Novo Nordisk A/S Sponsored ADR (NVO)
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
Wegovy and Ozempic are based on the same molecule called semaglutide. An investigation into the side effects of semaglutide was just published.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
We've had "diabesity"; now here's what "pre-diabesity" means for Novo Nordisk, Eli Lily et al
The surge in GLP-1 obesity-related research is highlighting a critical shift in medical literature, according to a recent analysis by Deutsche Bank. It notes that managing obesity is becoming increasingly vital, with terms like "diabesity"—the intersection of diabetes and obesity—gaining traction since 2023.
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?
A recent study claims that Ozempic is linked with a higher risk of suicidal thoughts than other drugs. However, other studies have reached the opposite conclusion.
Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
The rivalry between Novo Nordisk A/S NVO and Eli Lilly and Co LLY has heated up as both companies vie for dominance in the booming obesity-drug market. But for investors, the real story may lie beyond just weight-loss treatments.
Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation
The recent market correction and market's overreaction to the supposedly softer Wegovy sales have triggered NVO's discounted entry points. With Ozempic/Wegovy no longer in shortage and manufacturing capacity continuing to ramp up, it is unsurprising that the management has raised their FY2024 guidance. NVO continues to report robust GLP-1, obesity, and diabetic therapy market shares in the North American and International regions as well.
Novo Nordisk Pharmatech unit to build $220 mln plant in Denmark
Novo Nordisk's Pharmatech unit will build a 1.5 billion Danish crowns ($220.83 million) plant in Denmark to meet significantly higher demand for the production of medicines to fight chronic diseases, the company said on Friday.
Is Novo Nordisk's Earnings Miss a Cause for Concern for Investors?
Novo Nordisk's recent earnings numbers came in slightly lower than expectations. The company also reduced its forecast for earnings growth this year.
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 Stable Blue-Chip Stocks to Buy for the Market Storm
The volatility that has rocked markets since the beginning of July might not be over just yet. August has proven to be extremely rocky.
Here's How to Play Novo Nordisk (NVO) After Q2 Earnings Miss
Novo Nordisk (NVO) is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs. New investors should utilize the existing opportunity to make an entry.
Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
